Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

O Kirakosyan; M Reimann; A B Andersen; A Bjarnason; Á Bakos; A M Dyrhol-Riise; A M McLaughlin; C Nita; D Pieridou; D Chesov; E V Davidavičienė; G Günther; H Atshemyan; I Muylle; I Solovic; J Bruchfeld; K Manika; L Kuksa; L R Codecasa; M Stosic; M Skowroński; M J Makek; M Fréchet Jachym; M Knappik; M Santin; N Yatskevich; O Konstantynovska; O Akkerman; P Svetina; P Viiklepp; R Duarte; S Zeynel; T Togonidze; T Vasankari; V Parris; Ş Özkara; C Lange; T T Brehm

doi:10.5588/ijtldopen.24.0498

Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

O Kirakosyan, M Reimann, A B Andersen, A Bjarnason, Á Bakos, A M Dyrhol-Riise, A M McLaughlin, C Nita, D Pieridou, D Chesov, E V Davidavičienė, G Günther, H Atshemyan, I Muylle, I Solovic, J Bruchfeld, K Manika, L Kuksa, L R Codecasa, M StosicM Skowroński, M J Makek, M Fréchet Jachym, M Knappik, M Santin, N Yatskevich, O Konstantynovska, O Akkerman, P Svetina, P Viiklepp, R Duarte, S Zeynel, T Togonidze, T Vasankari, V Parris, Ş Özkara, C Lange^*, T T Brehm

^*Corresponding author for this work

Microbes in Health and Disease (MHD)

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Abstract

BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region.

METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group (TBnet) representatives in countries in the WHO European Region.

RESULTS: We received valid responses from 37 of 53 countries (69.8%), with 16 (43.2%) reporting regular use of putative hepatoprotective agents during anti-TB treatment. Half of these countries ( n = 8) are part of the former Soviet Union. In five countries, these agents are recommended by national guidelines. The most commonly used hepatoprotective agents were silibin/silymarin ( n = 9, 56.3%), ursodeoxycholic acid ( n = 5, 31.3%), and soy phospholipids ( n = 4, 25.0%). Treatment duration varied, with 56.3% ( n = 9) using them for less than 1 month, 18.8% ( n = 3) for 1-3 months, and 18.8% ( n = 3) for 4-6 months.

CONCLUSIONS: Putative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.

Original language	English
Pages (from-to)	101-106
Number of pages	6
Journal	IJTLD open
Volume	2
Issue number	2
DOIs	https://doi.org/10.5588/ijtldopen.24.0498
Publication status	Published - Feb-2025

Access to Document

10.5588/ijtldopen.24.0498Licence: CC BY

Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in EuropeFinal publisher's version, 1.45 MBLicence: CC BY

Handle.net

Persistent link

Cite this

Kirakosyan, O., Reimann, M., Andersen, A. B., Bjarnason, A., Bakos, Á., Dyrhol-Riise, A. M., McLaughlin, A. M., Nita, C., Pieridou, D., Chesov, D., Davidavičienė, E. V., Günther, G., Atshemyan, H., Muylle, I., Solovic, I., Bruchfeld, J., Manika, K., Kuksa, L., Codecasa, L. R., ... Brehm, T. T. (2025). Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe. IJTLD open, 2(2), 101-106. https://doi.org/10.5588/ijtldopen.24.0498

@article{286e363a70664e049ed3330703f3255b,

title = "Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe",

abstract = "BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region.METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group (TBnet) representatives in countries in the WHO European Region.RESULTS: We received valid responses from 37 of 53 countries (69.8%), with 16 (43.2%) reporting regular use of putative hepatoprotective agents during anti-TB treatment. Half of these countries ( n = 8) are part of the former Soviet Union. In five countries, these agents are recommended by national guidelines. The most commonly used hepatoprotective agents were silibin/silymarin ( n = 9, 56.3%), ursodeoxycholic acid ( n = 5, 31.3%), and soy phospholipids ( n = 4, 25.0%). Treatment duration varied, with 56.3% ( n = 9) using them for less than 1 month, 18.8% ( n = 3) for 1-3 months, and 18.8% ( n = 3) for 4-6 months. CONCLUSIONS: Putative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.",

author = "O Kirakosyan and M Reimann and Andersen, {A B} and A Bjarnason and {\'A} Bakos and Dyrhol-Riise, {A M} and McLaughlin, {A M} and C Nita and D Pieridou and D Chesov and Davidavi{\v c}ienė, {E V} and G G{\"u}nther and H Atshemyan and I Muylle and I Solovic and J Bruchfeld and K Manika and L Kuksa and Codecasa, {L R} and M Stosic and M Skowro{\'n}ski and Makek, {M J} and {Fr{\'e}chet Jachym}, M and M Knappik and M Santin and N Yatskevich and O Konstantynovska and O Akkerman and P Svetina and P Viiklepp and R Duarte and S Zeynel and T Togonidze and T Vasankari and V Parris and {\c S} {\"O}zkara and C Lange and Brehm, {T T}",

note = "{\textcopyright} 2025 The Authors.",

year = "2025",

month = feb,

doi = "10.5588/ijtldopen.24.0498",

language = "English",

volume = "2",

pages = "101--106",

journal = "IJTLD open",

issn = "3005-7590",

publisher = "International Union Against Tuberculosis and Lung Disease",

number = "2",

}

Kirakosyan, O, Reimann, M, Andersen, AB, Bjarnason, A, Bakos, Á, Dyrhol-Riise, AM, McLaughlin, AM, Nita, C, Pieridou, D, Chesov, D, Davidavičienė, EV, Günther, G, Atshemyan, H, Muylle, I, Solovic, I, Bruchfeld, J, Manika, K, Kuksa, L, Codecasa, LR, Stosic, M, Skowroński, M, Makek, MJ, Fréchet Jachym, M, Knappik, M, Santin, M, Yatskevich, N, Konstantynovska, O, Akkerman, O, Svetina, P, Viiklepp, P, Duarte, R, Zeynel, S, Togonidze, T, Vasankari, T, Parris, V, Özkara, Ş, Lange, C & Brehm, TT 2025, 'Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe', IJTLD open, vol. 2, no. 2, pp. 101-106. https://doi.org/10.5588/ijtldopen.24.0498

TY - JOUR

T1 - Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

AU - Kirakosyan, O

AU - Reimann, M

AU - Andersen, A B

AU - Bjarnason, A

AU - Bakos, Á

AU - Dyrhol-Riise, A M

AU - McLaughlin, A M

AU - Nita, C

AU - Pieridou, D

AU - Chesov, D

AU - Davidavičienė, E V

AU - Günther, G

AU - Atshemyan, H

AU - Muylle, I

AU - Solovic, I

AU - Bruchfeld, J

AU - Manika, K

AU - Kuksa, L

AU - Codecasa, L R

AU - Stosic, M

AU - Skowroński, M

AU - Makek, M J

AU - Fréchet Jachym, M

AU - Knappik, M

AU - Santin, M

AU - Yatskevich, N

AU - Konstantynovska, O

AU - Akkerman, O

AU - Svetina, P

AU - Viiklepp, P

AU - Duarte, R

AU - Zeynel, S

AU - Togonidze, T

AU - Vasankari, T

AU - Parris, V

AU - Özkara, Ş

AU - Lange, C

AU - Brehm, T T

PY - 2025/2

Y1 - 2025/2

N2 - BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region.METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group (TBnet) representatives in countries in the WHO European Region.RESULTS: We received valid responses from 37 of 53 countries (69.8%), with 16 (43.2%) reporting regular use of putative hepatoprotective agents during anti-TB treatment. Half of these countries ( n = 8) are part of the former Soviet Union. In five countries, these agents are recommended by national guidelines. The most commonly used hepatoprotective agents were silibin/silymarin ( n = 9, 56.3%), ursodeoxycholic acid ( n = 5, 31.3%), and soy phospholipids ( n = 4, 25.0%). Treatment duration varied, with 56.3% ( n = 9) using them for less than 1 month, 18.8% ( n = 3) for 1-3 months, and 18.8% ( n = 3) for 4-6 months. CONCLUSIONS: Putative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.

AB - BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region.METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group (TBnet) representatives in countries in the WHO European Region.RESULTS: We received valid responses from 37 of 53 countries (69.8%), with 16 (43.2%) reporting regular use of putative hepatoprotective agents during anti-TB treatment. Half of these countries ( n = 8) are part of the former Soviet Union. In five countries, these agents are recommended by national guidelines. The most commonly used hepatoprotective agents were silibin/silymarin ( n = 9, 56.3%), ursodeoxycholic acid ( n = 5, 31.3%), and soy phospholipids ( n = 4, 25.0%). Treatment duration varied, with 56.3% ( n = 9) using them for less than 1 month, 18.8% ( n = 3) for 1-3 months, and 18.8% ( n = 3) for 4-6 months. CONCLUSIONS: Putative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.

U2 - 10.5588/ijtldopen.24.0498

DO - 10.5588/ijtldopen.24.0498

M3 - Article

C2 - 39959402

SN - 3005-7590

VL - 2

SP - 101

EP - 106

JO - IJTLD open

JF - IJTLD open

IS - 2

ER -

Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

Abstract

Access to Document

Handle.net

Fingerprint

Cite this